ST. LOUIS, MO, UNITED STATES -- Pairidex, a precision diagnostics company advancing personalized molecular testing for hematologic malignancies, today announced the successful close of its oversubscribed Seed financing round. The financing brings in $4.89M in new capital to accelerate the commercial launch of FusionMRD™, the company's personalized, RNA-based laboratory developed test (LDT) for monitoring measurable residual disease (MRD) in fusion-driven...
Press & Updates
Explore the latest news and updates from Pairidex® as we progress along the path to delivering smarter, faster, and more compassionate blood cancer care.
Pairidex Closes Over-Subscribed Seed Round to Support the Launch of New Highly Sensitive MRD Test for Leukemia
Cancer MRD Testing Startup Pairidex Raises $4.9M in Seed Financing
NEW YORK – Cancer precision diagnostics startup Pairidex on Monday announced the close of a $4.89 million seed financing round. The St. Louis, Missouri-based company did not name the investor but said that it is a large, publicly held strategic company, and that the round was oversubscribed. The firm plans to use the funding to speed up commercialization of FusionMRD,...
Pairidex Secures Lead Investment from BioGenerator Ventures for the Launch of New Highly Sensitive MRD Test for LeukemiaReducing Uncertainty in the Care and Treatment of Blood Cancer
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ -- Pairidex, an emerging leader in leukemia detection, today announced a lead investment from BioGenerator Ventures that will enable the launch of FusionMRD™, a new personalized, RNA-based assay for the monitoring of measurable residual disease (MRD) in fusion-driven hematological malignancies. FusionMRD™ is commercially available as a laboratory developed test (LDT) for...